Next Article in Journal
The Genome-Wide Impact of Nipblb Loss-of-Function on Zebrafish Gene Expression
Next Article in Special Issue
Fluorescent Cytochemical Detection of Polyphosphates Associated with Human Platelets
Previous Article in Journal
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
Previous Article in Special Issue
Intravital Assessment of Blood Platelet Function. A Review of the Methodological Approaches with Examples of Studies of Selected Aspects of Blood Platelet Function
Open AccessArticle

PLGA-PEG Nanoparticles Show Minimal Risks of Interference with Platelet Function of Human Platelet-Rich Plasma

School of Pharmacy and Biomolecular Sciences, RCSI, University of Medicine and Health Sciences, D02 YN77 Dublin 2, Ireland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(24), 9716; https://doi.org/10.3390/ijms21249716
Received: 20 November 2020 / Revised: 9 December 2020 / Accepted: 15 December 2020 / Published: 19 December 2020
(This article belongs to the Special Issue Physiology of Platelets in Humans and Animals)
The expansion of nanotechnology for drug delivery applications has raised questions regarding the safety of nanoparticles (NPs) due to their potential for interacting at molecular and cellular levels. Although polymeric NPs for drug delivery are formulated using FDA-approved polymers such as lactide- and glycolide-based polymers, their interactions with blood constituents, remain to be identified. The aim of this study was to determine the impact of size-selected Poly-lactide-co-glycolide-polyethylene glycol (PLGA-PEG) NPs on platelet activity. The NPs of 113, 321, and 585 nm sizes, were formulated and their effects at concentrations of 0–2.2 mg/mL on the activation and aggregation of platelet-rich plasma (PRP) were investigated. The results showed that NPs of 113 nm did not affect adenosine diphosphate (ADP)-induced platelet aggregation at any NP concentration studied. The NPs of 321 and 585 nm, at concentrations ≥0.25 mg/mL, reduced ADP-activated platelet aggregation. The platelet activation profile remained unchanged in the presence of investigated NPs. Confocal microscopy revealed that NPs were attached to or internalised by platelets in both resting and activated states, with no influence on platelet reactivity. The results indicate minimal risks of interference with platelet function for PLGA-PEG NPs and that these NPs can be explored as nanocarriers for targeted drug delivery to platelets. View Full-Text
Keywords: PLGA-PEG; nanoparticles; particle size; platelet rich plasma; platelet activation; platelet aggregation PLGA-PEG; nanoparticles; particle size; platelet rich plasma; platelet activation; platelet aggregation
Show Figures

Figure 1

MDPI and ACS Style

Bakhaidar, R.; O’Neill, S.; Ramtoola, Z. PLGA-PEG Nanoparticles Show Minimal Risks of Interference with Platelet Function of Human Platelet-Rich Plasma. Int. J. Mol. Sci. 2020, 21, 9716. https://doi.org/10.3390/ijms21249716

AMA Style

Bakhaidar R, O’Neill S, Ramtoola Z. PLGA-PEG Nanoparticles Show Minimal Risks of Interference with Platelet Function of Human Platelet-Rich Plasma. International Journal of Molecular Sciences. 2020; 21(24):9716. https://doi.org/10.3390/ijms21249716

Chicago/Turabian Style

Bakhaidar, Rana; O’Neill, Sarah; Ramtoola, Zebunnissa. 2020. "PLGA-PEG Nanoparticles Show Minimal Risks of Interference with Platelet Function of Human Platelet-Rich Plasma" Int. J. Mol. Sci. 21, no. 24: 9716. https://doi.org/10.3390/ijms21249716

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop